Analysts tap Amgen, Celgene as potential 2012 dealmakers

Analysts are saying the world's biggest biotechs, including Amgen ($AMGN) and Celgene ($CELG), are likely to scout for big acquisitions this year as they seek to revive growth and refill pipelines, Bloomberg reports. Report